Evidence map›Paper›PMID 27121156›Full record

ReviewJapanese journal of radiology2016

Present and future roles of FDG-PET/CT imaging in the management of lung cancer.

Kazuhiro Kitajima, Hiroshi Doi, Tomonori Kanda, Tomohiko Yamane, Tetsuya Tsujikawa, Hayato Kaida, Yukihisa Tamaki, Kozo Kuribayashi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Japanese journal of radiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Diagnostic accuracy in NSCLC lymph node staging with Total-Body and conventional PET/CT.European journal of nuclear medicine and molecular imaging · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Characteristics of whole-body dynamicQuantitative imaging in medicine and surgery · 2024
    Article
  9. Article
  10. Tumor infiltrating lymphocytes and radiological picture of the tumor.Medical oncology (Northwood, London, England) · 2023
    Review
  11. Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[European journal of nuclear medicine and molecular imaging · 2022
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kazuhiro KitajimaDivision of Nuclear Medicine and PET Center, Department of Radiology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan. kitajima@med.kobe-u.ac.jp.
Hiroshi DoiDepartment of Radiology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan.
Tomonori KandaDepartment of Radiology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan.
Tomohiko YamaneDepartment of Nuclear Medicine, Saitama International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama, 350-1298, Japan.
Tetsuya TsujikawaDepartment of Biomedical Imaging Research Center, Fukui University, 23-3 Matsuoka-Shimoaizuki, Eiheiji-cho, Fukui, 910-1193, Japan.
Hayato KaidaDepartment of Radiology, Kinki University Faculty of Medicine, 377-2 Ohnohigashi, Osakasayama, Osaka, 589-8511, Japan.
Yukihisa TamakiDepartment of Radiation Oncology, Shimane University School of Medicine, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.
Kozo KuribayashiDivision of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Integrated positron emission tomography/computed tomography (PET/CT) using 2-[(18)F]fluoro-2-deoxy-D-glucose ((18)F-FDG) has emerged as a powerful tool for combined metabolic and anatomic evaluation in clinical oncologic imaging. This review discusses the utility of (18)F-FDG PET/CT as a tool for managing patients with lung cancer. We discuss different patient management stages, including diagnosis, initial staging, therapy planning, early treatment response assessment, re-staging, and prognosis.

Indexed as

Fluorodeoxyglucose F18Positron Emission Tomography Computed TomographyRadiopharmaceuticalsHumansLungLung NeoplasmsNeoplasm StagingRadiotherapy Planning, Computer-AssistedFluorodeoxyglucose F18RadiopharmaceuticalsFluorodeoxyglucose (FDG)Lung cancerPositron emission tomography/computed tomography (PET/CT)StagingTreatment response assessment

Identifiers

PMID27121156

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.